Summary of the Conference Call for稳健医疗 Company Overview - **Company**: 稳健医疗 (Steady Medical) - **Industry**: Medical and Consumer Products Key Points Financial Performance - In 2024, the company has recovered from the pandemic impact, achieving positive quarterly revenue growth and improving profitability, with continued growth in Q1 2025 [2][3] - The company set revenue growth targets of 13% to 18% for its medical and consumer segments through an equity incentive plan, boosting market confidence [2][3] Medical Segment - The medical segment has improved profitability through product structure adjustments, inventory management, and talent incentives, although it has not yet returned to pre-pandemic levels [2][4][5] - High-margin products like advanced dressings and health personal care items are gaining a larger share of the medical business [4] - The medical business has significant growth potential across various channels, including hospitals, OTC, and e-commerce [4][9] Consumer Segment - The consumer segment focuses on strategic categories such as cotton soft towels, sanitary napkins, newborn clothing, and adult personal wear, with cotton soft towels and sanitary napkins showing strong growth potential [2][5][8] - The company has shifted from a multi-SKU strategy to a focused strategy, enhancing brand recognition and reducing price competition [5] - The sanitary napkin market has shown limited impact from the 315 public opinion incident, with e-commerce data recovering [6][7] Market Potential - The cotton soft towel market is projected to exceed 10 billion yuan, with a growth rate of approximately 20% annually, while the sanitary napkin market is estimated between 30 billion to 40 billion yuan [8] - The company plans to leverage successful products for brand iteration and expand into new markets through user management and private domain operations [8] Long-term Outlook - Both the medical and consumer segments are expected to have significant growth potential, with the company positioned as a viable investment target despite short-term fluctuations due to the pandemic [9][10] - The company aims to continue its equity incentive goals and capitalize on the growth opportunities in both segments [10]

她们选择全棉产品的背后，正是对稳健集团"医学贴近生活，全棉呵护健康"理念的认同。在制造业回 归"产品力"、消费市场更加理性的大背景下，品牌不再只靠营销声量赢得注意，而是回归生产现场、回 归真实体验，用专业和透明赢得认可。 走进工厂：看得见的品质，是信任的起点 在央视财经《超级生产线》深度走访节目中，郭晶晶与陈伟鸿一同探访稳健医疗旗下棉柔巾生产基地。 从原材料储存区到洁净的自动化车间，两人见证了优质棉花如何在无菌无尘环境下，经过开松、梳理、 热轧等多个环节，最终转化为柔软强韧的棉柔巾成品。 郭晶晶感慨道："消费者使用的产品，卫生安全是重中之重，这样严格的生产把控，让人更放心。"她还 特别关注环保细节，包括工厂对可持续棉花的采购与先进的污水处理系统。陈伟鸿则指出："在追求产 品品质的同时不忘环保责任，这样的企业值得点赞。" 5月以来，稳健集团（股票简称：稳健医疗（300888），股票代码：300888.SZ）旗下全棉时代品牌活动 引发广泛关注：品牌代言人、前奥运冠军郭晶晶与知名主持人陈伟鸿走进全棉时代棉柔巾智能工厂，实 地探访产品制造全过程；作为全棉时代家居服全球代言人，赵丽颖则空降全棉时代京东直播间，亲自推 荐 ...

Trading Information Summary - On May 23, 2025, the stock price of Steady Medical (300888) closed at 48.88 yuan, down 1.21%, with a turnover rate of 2.18% and a trading volume of 38,300 shares, resulting in a transaction amount of 189 million yuan [1] - The fund flow on the same day indicated that the main funds had a net outflow of 11.97 million yuan, while speculative funds had a net outflow of 17.44 million yuan, and retail investors had a net inflow of 29.41 million yuan [1][3] Company Announcement Summary - Steady Medical announced its 2024 annual equity distribution plan, which was approved at the shareholders' meeting on May 21, 2025. The company will distribute a cash dividend of 2.50 yuan (including tax) for every 10 shares, totaling 145.58 million yuan [1] - The record date for the distribution is set for May 29, 2025, and the ex-dividend date is May 30, 2025. The cash dividends for A-share shareholders will be distributed by China Securities Shenzhen Branch, while some dividends will be distributed directly by the company [1] - The adjusted minimum selling price for shares is set at 48.90 yuan per share, and the grant price for the restricted stock incentive plan is adjusted to 15.14 yuan per share [1]

Core Viewpoint - The company,稳健医疗, reported a decline in stock price and provided key financial performance metrics for 2024, indicating growth in revenue and net profit despite a slight decrease in stock value [1][2]. Group 1: Financial Performance - In 2024, the company achieved a total revenue of 8.98 billion yuan, representing a year-on-year growth of 9.7%. Excluding infection prevention products, revenue reached 8.62 billion yuan, with an 18.6% increase [2][4]. - The net profit attributable to shareholders for the year was 700 million yuan, with a 19.8% year-on-year growth. After excluding non-recurring gains and losses, the net profit was 590 million yuan, reflecting a 43.4% increase [2][4]. - The diluted earnings per share for 2024 was 1.19 yuan, marking a 21.43% increase compared to the previous year [2]. Group 2: Cash Flow and Returns - The net cash flow from operating activities was 1.263 billion yuan [4]. - The weighted average return on equity was 6.07%, an increase of 1.04 percentage points year-on-year [2]. Group 3: Dividend Distribution - The board approved a cash dividend distribution plan of 2.50 yuan per 10 shares, with a record date of May 29, 2025, and an ex-dividend date of May 30, 2025 [3]. - The minimum price for share reduction was adjusted to 48.90 yuan per share, and the grant price for restricted stock incentive plans was set at 15.14 yuan per share [3].

Core Points - The company has announced its 2024 annual profit distribution plan, which was approved at the shareholders' meeting on May 21, 2025, involving a cash dividend of 2.50 RMB per 10 shares, totaling 145,582,452.00 RMB [1][2] Distribution Plan - The distribution is based on a total of 582,329,808 shares, with no stock dividends or capital reserves being converted into shares [1] - The cash dividend will be distributed to all shareholders, with specific tax considerations for different types of investors, including a reduced rate for certain foreign investors [1][2] Key Dates - The record date for the distribution is set for May 29, 2025, and the ex-dividend date is May 30, 2025 [2] Distribution Method - Cash dividends will be directly credited to the shareholders' accounts through their securities companies or other custodians [2] Adjustments - The ex-dividend price will be adjusted to reflect the cash dividend, reducing the previous trading day's closing price by 0.2500000 RMB per share [2] Shareholder Commitments - The controlling shareholder and actual controller have committed to a minimum selling price of 48.90 RMB per share for any shares sold within two years after the lock-up period [3] Incentive Plan Adjustments - The share price for the 2024 restricted stock incentive plan will be adjusted to 15.14 RMB per share following the completion of the profit distribution [4]

稳健医疗用品股份有限公司（以下简称"公司"或"本公司"）2024 年年度 权益分派方案已获 2025 年 5 月 21 日召开的 2024 年年度股东大会审议通过，现 将权益分派事宜公告如下： 一、股东大会审议通过的权益分派方案 1、公司 2024 年年度股东大会审议通过的权益分派方案为：以现有公司总股 本 582,329,808 股为基数，向全体股东每 10 股派发现金股利 2.50 元（含税）， 合计派发现金股利 145,582,452.00 元（（含税），不以公积金转增股本，不送红股， 剩余未分配利润滚存至下一年度。在利润分配预案披露至实施期间，若享有利润 分配权的股份总额发生变动，公司将按照现金分红比例不变、现金分红总金额变 化的原则进行相应调整。 稳健医疗用品股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：300888 证券简称：稳健医疗 公告编号：2025-016 2、自上述分配方案披露至实施期间，公司股本总额未发生变化。 3、本次实施的分配方案与股东大会审议通过的分配方案一致。 4、本次实 ...

证券代码：300888 证券简称：稳健医疗 公告编号：2025-015 稳健医疗用品股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1.本次股东大会无增加、变更、否决议案的情况； 2.本次股东大会未涉及变更以前股东大会决议的情形。 一、会议召开和出席情况 （一）股东大会届次：2024 年年度股东大会 （二）会议召集人：公司董事会 （三）会议召开时间： 2.网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 21 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体 时间为：2025 年 5 月 21 日 9:15-15:00。 （四）会议召开地点：广东省深圳市龙华区民治街道北站社区汇隆商务中心 2 号楼 42 层。 （五）会议召开方式：采取现场投票与网络投票相结合的方式。 （六）会议主持人：公司董事长李建全先生 （七）本次股东大会的召集、 ...

北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 北京市中伦（深圳）律师事务所 关于稳健医疗用品股份有限公司 2024 年年度股东大会的 法律意见书 二〇二五年五月 北京市中伦（深圳）律师事务所 关于稳健医疗用品股份有限公司 2024 年年度股东大会的 法律意见书 致：稳健医疗用品股份有限公司 根据中国证券监督管理委员会发布的《上市公司股东会规则（2025 年修订）》 （下称"《股东会规则》"）的有关规定，北京市中伦（深圳）律师事务所（下称 "本所"）接受稳健医疗用品股份有限公司（下称"公司"）的委托， ...

300888 Stock code： 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Winner Medical Co., Ltd. This report is prepared in accordance with the Self-Regulatory Guidelines No. 17 for Companies Listed on Shenzhen Stock Exchange—Sustainability Report (For Trial Implementation) , Self-Regulatory Guidelines No. 3 for Companies Listed on Shenzhen Stock Exchange—Sustainability Reporting Preparation and related documents of Shenzhen Stock Exchange. It also refers to the following standards and guidelines: GRI Sustainab ...

Investment Rating - The report maintains a "Buy" rating for key companies in the textile and apparel sector, including Anta Sports, Bosideng, and Chow Tai Fook [5][6]. Core Insights - The report highlights a shift in consumer preferences towards practicality and self-satisfaction, with younger consumers favoring experiential and personalized consumption [1][12]. - The outdoor and ancient gold jewelry segments are experiencing significant growth, driven by changing consumer behaviors and preferences [2][51]. Summary by Sections New Consumption Trends - The rise of "pragmatism" and "self-satisfaction" is evident as consumers become more rational in their purchasing decisions, moving away from traditional marketing [1][13]. - Young consumers are increasingly drawn to interactive and personalized shopping experiences, prioritizing comfort and natural materials [1][18]. Demand Trend Analysis - The outdoor sports market is expanding rapidly, with the market size for outdoor footwear and apparel reaching 45 billion yuan in 2023, growing at a compound annual growth rate (CAGR) of nearly 20% [22]. - The ancient gold jewelry market has seen its size grow from 13 billion yuan in 2018 to 157.3 billion yuan in 2023, indicating strong demand among younger consumers [51][56]. Competitive Factors - Companies are focusing on product innovation and brand storytelling to attract consumers, with significant marketing investments noted among leading brands [3][41]. - The report emphasizes the importance of maintaining a robust channel strategy, with leading companies upgrading store images and enhancing digital integration [4][60]. Investment Recommendations - Key recommendations include Anta Sports for its outdoor brand matrix, Bosideng for its functional apparel, and Chow Tai Fook for its strong brand power in the jewelry sector, with respective price-to-earnings (PE) ratios projected for 2025 [5][6].